


Basal and peripheral ganglia disorders: age and vaccine distribution, VAERS data* (U.S. and foreign), 1990.07–2024.08.30[†]

Draft v32.5



	Janssen COVID-19	Moderna COVID-19	Pfizer/BioNTech COVID-19	Unknown manufacturer COVID-19	All COVID-19 2020.12.14–2024.08.30	All non-COVID-19 1990.07–2020.12.13
<i>n</i> VAERS IDs	19	57	182	1	259	28
μ , Mean ^{‡‡} —	64.6	65.8	62.0	63.0	63.1	22.8
\hat{x} , Median ^{‡‡} —	66.0	66.0	66.0	63.0	66.0	3.3
σ , Standard deviation ^{‡‡}	14.1	14.1	19.9	—	18.3	30.4
γ , Skewness ^{‡‡}	−0.5	−0.3	−0.7	—	−0.7	−0.7
<i>n</i> Hospitalized	17	45	130	1	193	23
<i>n</i> Life threatening	4	17	51	0	72	4
<i>n</i> Recovered	4	10	16	1	31	2
<i>n</i> Not recovered	9	27	122	0	158	17
<i>n</i> Died	0	5	13	0	18	2

[†]Terms queried in SYMPTOM fields 1–5 include: basal ganglia (degeneration/haematoma/haemorrhage/infarction/stroke), ganglio- (neuroma/neuroblastoma), geniculate ganglionitis, multiple system atrophy, and paraganglion neoplasm.

^{‡‡}NLP was used to extract age values from SYMPTOM TEXT and fill in missing data. Remaining reports with unknown age are neither plotted, nor included in calculations, but are included in subtotals. [‡]Symbols link to OpenVAERS.

*VAERS disclaimer (excerpts): "... VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as 'safety signals'." "The inclusion of events in VAERS data does not infer causality." vaers.hhs.gov